

[Dermatol Surg.](#) 2018 Oct;44(10):1278-1286. doi: 10.1097/DSS.0000000000001556.

Adipose Stromal Vascular Fraction Gel Grafting: A New Method for Tissue Volumization and Rejuvenation.

[Yao Y](#)¹, [Cai J](#), [Zhang P](#), [Liao Y](#), [Yuan Y](#), [Dong Z](#), [Lu F](#)².

[Aesthet Surg J.](#) 2017 Oct 1;37(9):975-985. doi: 10.1093/asj/sjx115.

Mechanical Supplementation With the Stromal Vascular Fraction Yields Improved Volume Retention in Facial Lipotransfer: A 1-Year Comparative Study.

[Gontijo-de-Amorim NF](#)^{1,2}, [Charles-de-Sá L](#)^{1,2}, [Rigotti G](#)³.

[Stem Cell Res Ther.](#) 2017 Jun 15;8(1):145. doi: 10.1186/s13287-017-0598-y.

Adipose tissue-derived stromal vascular fraction in regenerative medicine: a brief review on biology and translation.

[Bora P](#)^{1,2}, [Majumdar AS](#)³¹, [Bourin P](#), [Bunnell BA](#), [Casteilla L](#), et al. [Stromal cells from the adipose tissue-derived stromal vascular fraction and culture expanded adipose tissue-derived stromal/stem cells: a joint statement of the International Federation for Adipose Therapeutics and Science \(IFATS\) and the International Society for Cellular Therapy \(ISCT\) Cytotherapy.](#) 2013;15:641–8. doi: 10.1016/j.jcyt.2013.02.006. [[PMC free article](#)][[PubMed](#)] [[CrossRef](#)]

2. Gimble JM, Bunnell BA, Frazier T, et al. Adipose-derived stromal/stem cells. *Organogenesis*. 2013;9:3–10. doi: 10.4161/org.24279. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]

3. Nguyen A, Guo J, Banyard DA, et al. Stromal vascular fraction: a regenerative reality? Part 1: current concepts and review of the literature. *J Plast Reconstr Aesthetic Surg.* 2016;69:170–9. doi: 10.1016/j.bjps.2015.10.015. [[PubMed](#)] [[CrossRef](#)]

4. Bunnell B, Flaat M, Gagliardi C, et al. Adipose-derived stem cells: isolation, expansion and differentiation. *Methods*. 2008;45:115–20. doi: 10.1016/j.ymeth.2008.03.006. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]

5. Casteilla L. Adipose-derived stromal cells: their identity and uses in clinical trials, an update. *World J Stem Cells*. 2011;3:25. doi: 10.4252/wjsc.v3.i4.25. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]

6. Suzuki E, Fujita D, Takahashi M, et al. Adipose tissue-derived stem cells as a therapeutic tool for cardiovascular disease. *World J Cardiol.* 2015;7:454–65. doi: 10.4330/wjc.v7.i11.707. [[PMC free article](#)][[PubMed](#)] [[CrossRef](#)]
7. Bony C, Cren M, Domergue S, et al. Adipose mesenchymal stem cells isolated after manual or water-jet-assisted liposuction display similar properties. *Front Immunol.* 2016;6:1–8. doi: 10.3389/fimmu.2015.00655. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
8. Mi HM, Sun YK, Yeon JK, et al. Human adipose tissue-derived mesenchymal stem cells improve postnatal neovascularization in a mouse model of hindlimb ischemia. *Cell Physiol Biochem.* 2006;17:279–90. doi: 10.1159/000094140. [[PubMed](#)] [[CrossRef](#)]
9. van Dijk A, Naaijken BA, Jurgens WJFM, et al. Reduction of infarct size by intravenous injection of uncultured adipose derived stromal cells in a rat model is dependent on the time point of application. *Stem Cell Res.* 2011;7:219–29. doi: 10.1016/j.scr.2011.06.003. [[PubMed](#)] [[CrossRef](#)]
10. Charles-de-Sá L, Gontijo-de-Amorim NF, Maeda Takiya C, et al. Antiaging treatment of the facial skin by fat graft and adipose-derived stem cells. *Plast Reconstr Surg.* 2015;135:999–1009. doi: 10.1097/PRS.0000000000001123. [[PubMed](#)] [[CrossRef](#)]
11. Semon JA, Zhang X, Pandey AC, et al. Administration of murine stromal vascular fraction ameliorates chronic experimental autoimmune encephalomyelitis. *Stem Cells Transl Med.* 2013;2:789–96. doi: 10.5966/sctm.2013-0032. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
12. You D, Jang MJ, Kim BH, et al. Comparative study of autologous stromal vascular fraction and adipose-derived stem cells for erectile function recovery in a rat model of cavernous nerve injury. *Stem Cells Transl Med.* 2015;4:351–8. doi: 10.5966/sctm.2014-0161. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
13. Mohammadi R, Sanaei N, Ahsan S, et al. Stromal vascular fraction combined with silicone rubber chamber improves sciatic nerve regeneration in diabetes. *Chinese J Traumatol.* 2015;18:212–8. doi: 10.1016/j.cjte.2014.10.005. [[PubMed](#)] [[CrossRef](#)]

14. Yoshimura K, Sato K, Aoi N, et al. Cell-assisted lipotransfer for cosmetic breast augmentation: supportive use of adipose-derived stem/stromal cells. *Aesthetic Plast Surg.* 2008;32:48–55. doi: 10.1007/s00266-007-9019-4. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
15. Pak J, Chang J-J, Lee JH, et al. Safety reporting on implantation of autologous adipose tissue-derived stem cells with platelet-rich plasma into human articular joints. *BMC Musculoskelet Disord.* 2013;14:337. doi: 10.1186/1471-2474-14-337. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
16. Yoshimura K, Suga H, Eto H. Adipose-derived stem/progenitor cells: roles in adipose tissue remodeling and potential use for soft tissue augmentation. *Regen Med.* 2009;4:265–73. doi: 10.2217/17460751.4.2.265. [[PubMed](#)] [[CrossRef](#)]
17. Matsumoto D, Sato K, Gonda K, et al. Cell-assisted lipotransfer: supportive use of human adipose-derived cells for soft tissue augmentation with lipoinjection. *Tissue Eng.* 2006;12:3375–82. doi: 10.1089/ten.2006.12.3375. [[PubMed](#)] [[CrossRef](#)]
18. Silva FJ, Holt DJ, Vargas V, et al. Metabolically active human brown adipose tissue derived stem cells. *Stem Cells.* 2014;32:572–81. doi: 10.1002/stem.1595. [[PubMed](#)] [[CrossRef](#)]
19. Gimble JM, Katz AJ, Bunnell BA. Adipose-derived stem cells for regenerative medicine. *Circ Res.* 2007;100:1249–60. doi: 10.1161/01.RES.0000265074.83288.09. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
20. Colen BD. A pill to shed fat? Harvard stem cell researchers say they finally can turn “bad” fat into “good.” *Harvard Gaz* 2014. <http://news.harvard.edu/gazette/story/2014/12/a-pill-to-shed-fat/>. Accessed 8 Sept 2016.
21. Moisan A, Lee Y-K, Zhang JD, et al. White-to-brown metabolic conversion of human adipocytes by JAK inhibition. *Nat Cell Biol.* 2014;17:57–67. doi: 10.1038/ncb3075. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]

22. Oberbauer E, Steffenhagen C, Wurzer C, et al. Enzymatic and non-enzymatic isolation systems for adipose tissue-derived cells: current state of the art. *Cell Regen*. 2015;4:7. doi: 10.1186/s13619-015-0020-0. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
23. Tonnard P, Verpaele A, Peeters G, et al. Nanofat grafting: basic research and clinical applications. *Plast Reconstr Surg*. 2013;132:1017–26. doi: 10.1097/PRS.0b013e31829fe1b0. [[PubMed](#)] [[CrossRef](#)]
24. Aronowitz JA, Lockhart RA, Hakakian CS. Mechanical versus enzymatic isolation of stromal vascular fraction cells from adipose tissue. *Springerplus*. 2015;4:713. doi: 10.1186/s40064-015-1509-2. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
25. Shah FS, Wu X, Dietrich M, et al. A non-enzymatic method for isolating human adipose tissue-derived stromal stem cells. *Cytotherapy*. 2013;15:979–85. doi: 10.1016/j.jcyt.2013.04.001. [[PubMed](#)] [[CrossRef](#)]
26. Guo J, Nguyen A, Banyard DA, et al. Stromal vascular fraction: a regenerative reality? Part 2: mechanisms of regenerative action. *J Plast Reconstr Aesthetic Surg*. 2016;69:180–8. doi: 10.1016/j.bjps.2015.10.014. [[PubMed](#)] [[CrossRef](#)]
27. Dominici M, Le Blanc K, Mueller I, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. *Cytotherapy*. 2006;8:315–7. doi: 10.1080/14653240600855905. [[PubMed](#)] [[CrossRef](#)]
28. Zuk PA, Zhu M, Mizuno H, et al. Multilineage cells from human adipose tissue: implications for cell-based therapies. *Tissue Eng*. 2001;7:211–28. doi: 10.1089/107632701300062859. [[PubMed](#)] [[CrossRef](#)]
29. SundarRaj S, Deshmukh A, Priya N, et al. Development of a system and method for automated isolation of stromal vascular fraction from adipose tissue lipoaspirate. *Stem Cells Int*. 2015;2015:1–11. doi: 10.1155/2015/109353. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
30. Riis S, Zachar V, Boucher S, et al. Critical steps in the isolation and expansion of adipose-derived stem cells for translational therapy. *Expert Rev Mol Med*. 2015;17:e11. doi: 10.1017/erm.2015.10. [[PubMed](#)] [[CrossRef](#)]

31. Tamburino S, Lombardo GA, Tarico MS, et al. The role of nanofat grafting in vulvar lichen sclerosus: a preliminary report. *Arch Plast Surg*. 2016;43:93. doi: 10.5999/aps.2016.43.1.93. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
32. Kemaloğlu CA. Nanofat grafting under a split-thickness skin graft for problematic wound management. *Springerplus*. 2016;5:138. doi: 10.1186/s40064-016-1808-2. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
33. Fraser JK, Hicok KC, Shanahan R, et al. The Celution(®) system: automated processing of adipose-derived regenerative cells in a functionally closed system. *Adv Wound Care*. 2014;3:38–45. doi: 10.1089/wound.2012.0408. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
34. Invitrogen™ Countess™. Invitrogen cell data sheet-ADSC. <http://www.thermofisher.com/content/dam/LifeTech/migration/en/filelibrary/cell-tissue-analysis/pdfs.par.71179.file.dat/co13964-stem-cell-data-sheet-adsc.pdf>. Accessed 7 Sept 2016.
35. Sponsored paper. Rapid analysis of human adipose-derived stem cells and 3 T3-L1 differentiation toward adipocytes using the Scepter™ 2.0 cell counter. *Biotechniques*. 2012;53:109–11.
36. Ryu YJ, Cho TJ, Lee DS, et al. Phenotypic characterization and in vivo localization of human adipose-derived mesenchymal stem cells. *Mol Cells*. 2013;35:557–64. doi: 10.1007/s10059-013-0112-z. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
37. Asahara T, Kawamoto A, Masuda H. Concise review: circulating endothelial progenitor cells for vascular medicine. *Stem Cells*. 2011;29:1650–5. doi: 10.1002/stem.745. [[PubMed](#)] [[CrossRef](#)]
38. Garipcan B, Maenz S, Pham T, et al. Image analysis of endothelial microstructure and endothelial cell dimensions of human arteries—a preliminary study. *Adv Eng Mater*. 2011;13:B54–7. doi: 10.1002/adem.201080076. [[CrossRef](#)]
39. Bergman RA, Afifi AK, Heidger PM. *Anatomy atlases: atlas of microscopic anatomy: section 4—blood*. Plate 4.53:

lymphocytes. <http://www.anatomyatlases.org/MicroscopicAnatomy/Section04/Plate0453.shtml>. Accessed 7 Sept 2016.

40. Rosenbluth MJ, Lam WA, Fletcher DA. Force microscopy of nonadherent cells: a comparison of leukemia cell deformability. *Biophys J*. 2006;90:2994–3003. doi: 10.1529/biophysj.105.067496. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]

41. Krombach F, Münzing S, Allmeling AM, et al. Cell size of alveolar macrophages: an interspecies comparison. *Environ Health Perspect*. 1997;105:1261–3. doi: 10.1289/ehp.97105s51261. [[PMC free article](#)][[PubMed](#)] [[CrossRef](#)]

42. Duke University Medical School. Histology learning resources. <https://web.duke.edu/histology/MoleculesCells/Muscle/Muscle.html#webslide96>. Accessed 7 Sept 2016.

43. Duke University Medical School. Histology learning resources. <https://web.duke.edu/histology/MoleculesCells/Muscle/muscle.jpg>. Accessed 7 Sept 2016.

44. Proebstl D, Voisin M-B, Woodfin A, et al. Pericytes support neutrophil subendothelial cell crawling and breaching of venular walls in vivo. *J Exp Med*. 2012;209:1219–34. doi: 10.1084/jem.20111622. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]

45. Lai N, Sims JK, Jeon NL, et al. Adipocyte induction of preadipocyte differentiation in a gradient chamber. *Tissue Eng Part C Methods*. 2012;18:958–67. doi: 10.1089/ten.tec.2012.0168. [[PMC free article](#)][[PubMed](#)] [[CrossRef](#)]

46. Traktuev DO, Merfeld-Clauss S, Li J, et al. A population of multipotent CD34-positive adipose stromal cells share pericyte and mesenchymal surface markers, reside in a periendothelial location, and stabilize endothelial networks. *Circ Res*. 2008;102:77–85. doi: 10.1161/CIRCRESAHA.107.159475. [[PubMed](#)] [[CrossRef](#)]

47. Traktuev DO, Prater DN, Merfeld-Clauss S, et al. Robust functional vascular network formation in vivo by cooperation of adipose progenitor and endothelial cells. *Circ Res*. 2009;104:1410–20. doi: 10.1161/CIRCRESAHA.108.190926. [[PubMed](#)] [[CrossRef](#)]

48. Pallua N, Serin M, Wolter TP. Characterisation of angiogenetic growth factor production in adipose tissue-derived mesenchymal cells. *J Plast Surg Hand Surg.* 2014;48:412–6. doi: 10.3109/2000656X.2014.903196. [[PubMed](#)] [[CrossRef](#)]
49. Grasys J, Kim B, Pallua N. Content of soluble factors and characteristics of stromal vascular fraction cells in lipoaspirates from different subcutaneous adipose tissue depots. *Aesthetic Surg J.* 2016;36:831–41. doi: 10.1093/asj/sjw022. [[PubMed](#)] [[CrossRef](#)]
50. Szöke K, Brinchmann JE. Concise review: therapeutic potential of adipose tissue-derived angiogenic cells. *Stem Cells Transl Med.* 2012;1:658–67. doi: 10.5966/sctm.2012-0069. [[PMC free article](#)][[PubMed](#)] [[CrossRef](#)]
51. Crisan M, Yap S, Casteilla L, et al. A perivascular origin for mesenchymal stem cells in multiple human organs. *Cell Stem Cell.* 2008;3:301–13. doi: 10.1016/j.stem.2008.07.003. [[PubMed](#)] [[CrossRef](#)]
52. Maumus M, Peyrafitte J-A, D'Angelo R, et al. Native human adipose stromal cells: localization, morphology and phenotype. *Int J Obes.* 2011;35:1141–53. doi: 10.1038/ijo.2010.269. [[PMC free article](#)][[PubMed](#)] [[CrossRef](#)]
53. Lin C-S, Ning H, Lin G, et al. Is CD34 truly a negative marker for mesenchymal stromal cells? *Cytotherapy.* 2012;14:1159–63. doi: 10.3109/14653249.2012.729817. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
54. Suga H, Matsumoto D, Eto H, et al. Functional implications of CD34 expression in human adipose-derived stem/progenitor cells. *Stem Cells Dev.* 2009;18:1201–10. doi: 10.1089/scd.2009.0003. [[PubMed](#)] [[CrossRef](#)]
55. Sidney LE, Branch MJ, Dunphy SE, et al. Concise review: evidence for CD34 as a common marker for diverse progenitors. *Stem Cells.* 2014;32:1380–9. doi: 10.1002/stem.1661. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
56. Scherberich A, Di Maggio N, McNagny KM. A familiar stranger: CD34 expression and putative functions in SVF cells of adipose tissue. *World J Stem Cells.* 2013;5:1–8. doi: 10.4252/wjsc.v5.i1.1.[[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]

57. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. *Cell*. 2007;129:465–72. doi: 10.1016/j.cell.2007.04.019. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
58. Das R, Jahr H, van Osch GJVM, et al. The role of hypoxia in bone marrow-derived mesenchymal stem cells: considerations for regenerative medicine approaches. *Tissue Eng Part B Rev*. 2010;16:159–68. doi: 10.1089/ten.teb.2009.0296. [[PubMed](#)] [[CrossRef](#)]
59. Ejtehadifar M, Shamsasenjan K, Movassaghpour A, et al. The effect of hypoxia on mesenchymal stem cell biology. *Adv Pharm Bull*. 2015;5:141–9. doi: 10.15171/apb.2015.021. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
60. Beegle J, Lakatos K, Kalomoiris S, et al. Hypoxic preconditioning of mesenchymal stromal cells induces metabolic changes, enhances survival, and promotes cell retention in vivo. *Stem Cells*. 2015;33:1818–28. doi: 10.1002/stem.1976. [[PubMed](#)] [[CrossRef](#)]
61. Haque N, Rahman MT, Abu Kasim NH, et al. Hypoxic culture conditions as a solution for mesenchymal stem cell based regenerative therapy. *Sci World J*. 2013;2013:1–12. doi: 10.1155/2013/632972. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
62. Grayson WL, Zhao F, Bunnell B, et al. Hypoxia enhances proliferation and tissue formation of human mesenchymal stem cells. *Biochem Biophys Res Commun*. 2007;358:948–53. doi: 10.1016/j.bbrc.2007.05.054. [[PubMed](#)] [[CrossRef](#)]
63. Feng Y, Zhu M, Dangelmajer S, et al. Hypoxia-cultured human adipose-derived mesenchymal stem cells are non-oncogenic and have enhanced viability, motility, and tropism to brain cancer. *Cell Death Dis*. 2014;5:e1567. doi: 10.1038/cddis.2014.521. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
64. Brunet De La Grange P, Barthe C, Lippert E, et al. Oxygen concentration influences mRNA processing and expression of the CD34 gene. *J Cell Biochem*. 2006;97:135–44. doi: 10.1002/jcb.20597. [[PubMed](#)] [[CrossRef](#)]
65. Rigotti G, Marchi A, Galie M, et al. Clinical treatment of radiotherapy tissue damage by lipoaspirate transplant: a healing process mediated by adipose-derived adult stem cells. *Plast*

Reconstr Surg. 2007;119:1409–22. doi: 10.1097/01.prs.0000256047.47909.71. [[PubMed](#)]
[[CrossRef](#)]

66. Prins H-J, Schulten EAJM, ten Bruggenkate CM, et al. Bone regeneration using the freshly isolated autologous stromal vascular fraction of adipose tissue in combination with calcium phosphate ceramics. *Stem Cells Transl Med*. 2016;5:1362–74. doi:

10.5966/sctm.2015-0369. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]

67. Haahr MK, Jensen CH, Toyserkani NM, et al. Safety and potential effect of a single intracavernous injection of autologous adipose-derived regenerative cells in patients with erectile dysfunction following radical prostatectomy: an open-label phase I clinical

trial. *EBioMedicine*. 2016;5:204–10. doi: 10.1016/j.ebiom.2016.01.024. [[PMC free article](#)][[PubMed](#)] [[CrossRef](#)]

68. Tocco I, Widgerow AD, Lalezari S, et al. Lipotransfer: the potential from bench to bedside. *Ann Plast Surg*. 2014;72:599–609. doi:

10.1097/SAP.0000000000000154. [[PubMed](#)] [[CrossRef](#)]

69. Doi K, Tanaka S, Iida H, et al. Stromal vascular fraction isolated from lipo-aspirates using an automated processing system: bench and bed analysis. *J Tissue Eng Regen Med*. 2013;7:864–70. doi: 10.1002/term.1478. [[PubMed](#)] [[CrossRef](#)]

70. Rigotti G, Charles-de-Sá L, Gontijo-de-Amorim NF, et al. Expanded stem cells, stromal-vascular fraction, and platelet-rich plasma enriched fat: comparing results of different facial rejuvenation approaches in a clinical trial. *Aesthet Surg J*. 2016;36:261–70.

doi: 10.1093/asj/sjv231.[[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]

71. Jackson WM, Nesti LJ, Tuan RS. Concise review: clinical translation of wound healing therapies based on mesenchymal stem cells. *Stem Cells Transl Med*. 2012;1:44–50. doi:

10.5966/sctm.2011-0024.[[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]

72. Borowski DW, Gill TS, Agarwal AK, et al. Autologous adipose-tissue derived regenerative cells for the treatment of complex cryptoglandular fistula-in-ano: a report of three cases. *BMJ Case Rep*. 2012;2012:4–7. doi: 10.1136/bcr-2012-006988. [[PMC free](#)

[article](#)] [[PubMed](#)] [[CrossRef](#)]

73. Riordan NH, Ichim TE, Min W-P, et al. Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. *J Transl Med.* 2009;7:29. doi: 10.1186/1479-5876-7-29. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
74. Lee HC, An SG, Lee HW, et al. Safety and effect of adipose tissue-derived stem cell implantation in patients with critical limb ischemia. *Circ J.* 2012;76:1750–60. doi: 10.1253/circj.CJ-11-1135. [[PubMed](#)] [[CrossRef](#)]
75. Parcerro JJ, Perez JA, Patel AN, et al. Autologous adipose-derived stromal stem cell implantation to resolve critical limb ischemia: case report. *Cureus.* 2014;6(5):e182. doi:10.7759/cureus.182. <http://www.cureus.com/articles/2376-autologous-adipose-derived-stromal-stem-cell-implantation-to-resolve-critical-limb-ischemia-case-report>.
76. Pers Y-M, Rackwitz L, Ferreira R, et al. Adipose mesenchymal stromal cell-based therapy for severe osteoarthritis of the knee: a phase I dose-escalation trial. *Stem Cells Transl Med.* 2016;5:847–56. doi: 10.5966/sctm.2015-0245. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
77. Domergue S, Bony C, Maumus M, et al. Comparison between stromal vascular fraction and adipose mesenchymal stem cells in remodeling hypertrophic scars. *PLoS One.* 2016;11:e0156161. doi: 10.1371/journal.pone.0156161. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
78. Frazier TP, Bowles A, Lee S, et al. Serially transplanted nonpericytic CD146– adipose stromal/stem cells in silk bioscaffolds regenerate adipose tissue in vivo. *Stem Cells.* 2016;34:1097–111. doi: 10.1002/stem.2325. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
79. Lin S-D, Huang S-H, Lin Y-N, et al. Injected implant of uncultured stromal vascular fraction loaded onto a collagen gel. *Ann Plast Surg.* 2016;76:S108–16. doi: 10.1097/SAP.0000000000000687. [[PubMed](#)] [[CrossRef](#)]
80. NEWSmax. Unregulated stem cell industry is “wild west.” NEWSmax; 2015. <http://www.newsmax.com/Health/Health-News/stem-cells-treatments-regulation/2015/05/18/id/645186/>. Accessed 7 Sept 2016.

81. McFarling UL. FDA moves to crack down on unproven stem cell therapies. STAT News. 2016. <https://www.statnews.com/2016/02/08/fda-crackdown-stem-cell-clinics/>. Accessed 7 Sept 2016.
82. Jabr F. In the flesh: the embedded dangers of untested stem cell cosmetics. Sci Am. 2012. Available at <http://www.scientificamerican.com/article/stem-cell-cosmetics/>. Accessed 7 Sept 2016.
83. Wilson C. Stem cell treatment causes nasal growth in woman's back. New Sci. 2014. <https://www.newscientist.com/article/dn25859-stem-cell-treatment-causes-nasal-growth-in-womans-back/>. Accessed 7 Sept 2016.
84. Cyranoski D. Korean deaths spark inquiry. Nature. 2010;468:485. doi: 10.1038/468485a. [[PubMed](#)] [[CrossRef](#)]
85. McLean AK, Stewart C, Kerridge I. Untested, unproven, and unethical: the promotion and provision of autologous stem cell therapies in Australia. Stem Cell Res Ther. 2015;6:12. doi: 10.1186/s13287-015-0047-8. [[PMC free article](#)] [[PubMed](#)] [[CrossRef](#)]
86. Ledford H. Boom in unproven cell therapies intensifies regulatory debate. Nature. 2016;537:148. doi: 10.1038/537148a. [[PubMed](#)] [[CrossRef](#)]
87. US Department of Health and Human Services (Food and Drug Administration). Human cells, tissues, and cellular- and tissue-based products (HCT/Ps) from adipose tissue : regulatory considerations; draft guidance. http://www.fda.gov/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Tissue/ucm427795.htm#HCT_QUESTION. Accessed 7 Sept 2016.
88. Turner L, Knoepfler P. Selling stem cells in the USA: assessing the direct-to-consumer industry. Cell Stem Cell. 2016;19:154–7. doi: 10.1016/j.stem.2016.06.007. [[PubMed](#)] [[CrossRef](#)]
89. Kirk MS, Manchin J, Collins SM. REGROW Act. Congress.gov 2016. <https://www.congress.gov/bill/114th-congress/senate-bill/2689/cosponsors>. Accessed 7 Sept 2016.

90. Research MJFF for P. MJFF signs letter opposing the REGROW Act
2016. <https://www.michaeljfox.org/foundation/news-detail.php?mjff-signs-letter-opposing-the-regrow-act>. Accessed 7 Sept 2016.
91. International Society for Cellular Therapy. ISCT calls for changes to proposed US REGROW Act on cell therapies
2016. <http://www.celltherapysociety.org/news/news.asp?id=304128&hhSearchTerms=%22regrow%22>. Accessed 7 Sept 2016.
92. The Alliance for Regenerative Medicine. ARM statement in response to U.S. Senator Kirk's REGROW Act. http://alliancerm.org/sites/default/files/ARMSenatorKirk_REGROWActletter_March2016_.pdf. Accessed 7 Sept 2016.
93. Knoepfler P. California stem-cell institute's political gamble. San Fr Chron
2016. <http://www.sfchronicle.com/opinion/article/California-stem-cell-institute-s-political-8250137.php?t=4c01ff1973cefdcb88&cmpid=twitter-premium>. Accessed 7 Sept 2016.
94. Joseph A. Drive to get more patients experimental stem cell treatments stirs concern. STAT News 2016. <https://www.statnews.com/2016/06/30/stem-cell-political-fight>. Accessed 7 Sept 2016.
95. Hass R, Kasper C, Böhm S, et al. Different populations and sources of human mesenchymal stem cells (MSC): a comparison of adult and neonatal tissue-derived MSC. *Cell Commun Signal*. 2011;9:12. doi: 10.1186/1478-811X-9-12